Pyelonephritis – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Sat, 20 Jun 2026 04:03:53 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Pyelonephritis – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Comparing the effectiveness of 7 days versus 14 days of ciprofloxacin or ceftriaxone for treating kidney infection in kidney transplant recipients https://clinicaltrials.eu/trial/comparing-the-effectiveness-of-7-days-versus-14-days-of-ciprofloxacin-or-ceftriaxone-for-treating-kidney-infection-in-kidney-transplant-recipients/ Wed, 29 Apr 2026 15:09:16 +0000 https://clinicaltrials.eu/trial/comparing-the-effectiveness-of-7-days-versus-14-days-of-ciprofloxacin-or-ceftriaxone-for-treating-kidney-infection-in-kidney-transplant-recipients/ This study focuses on Graft Pyelonephritis, which is a type of infection in the kidney that has been transplanted into a patient. The purpose of the study is to determine if a shorter course of antibiotic treatment lasting 7 days is as effective and safe as the standard 14-day treatment course.

Participants in the study will receive different types of antibiotics. Some may receive Ceftriaxone, which is administered through an Intravenous line, meaning the medicine is delivered directly into a vein. Others may receive Ciprofloxacin. The study compares these medications when given for a shorter period versus the usual longer period to see if the shorter duration provides the same level of healing and safety.

]]> Study on the Effectiveness and Safety of Cefepime/Nacubactam and Aztreonam/Nacubactam for Adults with Resistant Bacterial Infections https://clinicaltrials.eu/trial/study-on-the-effectiveness-and-safety-of-cefepime-nacubactam-and-aztreonam-nacubactam-for-adults-with-resistant-bacterial-infections/ Wed, 29 Apr 2026 15:00:18 +0000 https://clinicaltrials.eu/trial/study-on-the-effectiveness-and-safety-of-cefepime-nacubactam-and-aztreonam-nacubactam-for-adults-with-resistant-bacterial-infections/ This clinical trial is focused on studying the effectiveness and safety of two treatment combinations for certain serious infections. The diseases being studied include complicated urinary tract infection, acute uncomplicated pyelonephritis (a type of kidney infection), hospital-acquired bacterial pneumonia, ventilator-associated bacterial pneumonia, and complicated intra-abdominal infection. These infections are caused by a group of bacteria known as carbapenem-resistant Enterobacterales, which are difficult to treat due to their resistance to many antibiotics.

The trial will compare the treatment combinations of cefepime/nacubactam and aztreonam/nacubactam against the best available therapy currently used for these infections. Cefepime and aztreonam are antibiotics, while nacubactam is a substance that helps these antibiotics work better against resistant bacteria. The study will involve administering these treatments through an intravenous infusion, which means the medication is given directly into a vein.

Participants in the study will receive one of the treatment combinations or the best available therapy for up to 14 days. The goal is to determine which treatment is most effective in achieving overall treatment success across all the infection types mentioned. The study will also monitor the safety of the treatments to ensure they are safe for use in patients. This trial aims to provide valuable information that could lead to better treatment options for these challenging infections.

]]> Study on 7-Day vs. 14-Day Antibiotic Treatment for Kidney Infection in Transplant Patients Using Bromhexine Hydrochloride, Trimethoprim, and Fluoroquinolones https://clinicaltrials.eu/trial/study-on-7-day-vs-14-day-antibiotic-treatment-for-kidney-infection-in-transplant-patients-using-bromhexine-hydrochloride-trimethoprim-and-fluoroquinolones/ Wed, 29 Apr 2026 14:28:12 +0000 https://clinicaltrials.eu/trial/study-on-7-day-vs-14-day-antibiotic-treatment-for-kidney-infection-in-transplant-patients-using-bromhexine-hydrochloride-trimethoprim-and-fluoroquinolones/ This clinical trial is focused on studying the treatment of acute pyelonephritis, a type of kidney infection, in individuals who have received a kidney transplant. The study aims to determine if a 7-day course of antibiotics is as effective as a 14-day course in treating this condition. Participants in the trial will receive one of the following antibiotics: beta-lactam antibacterials, which include penicillins, sulfamethoxazole and trimethoprim, or fluoroquinolones. These medications are commonly used to treat bacterial infections.

The purpose of the study is to compare the effectiveness of the shorter and longer antibiotic treatments. Participants will be randomly assigned to receive either a 7-day or a 14-day course of antibiotics. The study will monitor the participants’ health and recovery over a period of time to assess the effectiveness of the treatment. This will include checking for the resolution of symptoms such as fever and urinary tract infection signs, as well as ensuring no additional antibiotic treatment is needed up to 30 days after the initial treatment.

Throughout the study, participants will be observed for any potential side effects from the antibiotics and their overall kidney function will be assessed. The study will also track the incidence of any relapse or recurrence of the infection, as well as the presence of antibiotic-resistant bacteria. The goal is to ensure that the shorter treatment is not less effective than the longer one, potentially leading to a change in standard treatment practices for kidney transplant recipients with acute pyelonephritis.

]]>